

Public Comment Policy

August 7, 2017

In accordance with the State of Mississippi's Open Meetings Act, the Mississippi Division of Medicaid (DOM) Pharmacy and Therapeutics (P&T) Committee meetings are open to the public. This law requires that a public announcement of the meetings be made two weeks prior to the scheduled meeting date. Except for specific pricing information, proprietary information or confidential information, the records of the P&T Committee are available to the public as well.

The purpose of this policy is to outline the P&T public comment process. DOM's goal is to continue to streamline the meeting processes, while providing an opportunity for comment from pharmaceutical industry representatives and other interested parties.

P&T Committee Policy for Public Comment

- A. Public comment during the P&T Committee Meeting is not open to the general public. However representatives from the pharmaceutical industry and advocacy/special interest groups may register to speak in advance of the meeting.
- B. Content is limited to drugs relevant to the drug classes on the agenda to be discussed during the meeting.
- C. Registration prior to the P&T Committee Meeting is required. Speakers may register one (1) month in advance of the meeting date.
- D. Speakers must sign in at least ten (10) minutes prior to the start of the meeting; otherwise the speaker will not be permitted to speak during the public comment period.
- E. Presentations
 - a. The Chair will recognize the speakers according to the order in which they are listed on the sign in sheet.
 - b. Speakers may only provide oral presentations; no visual or audio aids may be used.
 - c. Per the request of the Committee, no written documents or handouts are to be provided to the Committee members prior to and/or during the meeting.
 - d. Speakers shall limit their presentation to three (3) minutes per drug/per class/per manufacturer.
 - e. The presentation should focus on the clinical advantages of the particular product and shall refrain from criticizing the products from competitors.
- F. No questions or comments from the audience will be entertained unless approval is granted by two-thirds of the members present at the meeting.
- G. The Committee reserves the right to suspend or eliminate the period for public comment if the privilege becomes abused or is deemed to be non-productive.

To review the full Policy for Public Comment, please visit

<https://medicaid.ms.gov/providers/pharmacy/pharmacy-and-therapeutics-committee/>.